Kiniksa Pharmaceuticals International, plc financial statements

Income statement, balance sheet and cash flow statement for the last 9 fiscal years, taken from the XBRL data Kiniksa Pharmaceuticals International, plc files with the SEC in its annual reports.

In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.

Income statement

	FY2018	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Revenue					38.5	220	270	423	678
Cost of revenue					9.1	22.9	33.4	60.9	77.7
Gross profit					29.4	197	237	362	600
Research and development	56.4	86.6	135	112	99.3	65.5	76.1	112	96.9
Selling, general and administrative			35	45.3	85.9	98	129	168	196
General and administrative	9.04	21.6	35	45.3
Operating expenses	65.4	108	170	157
Operating income	-65.4	-108	-170	-157	-157	9.77	-25.2	-45.6	77.2
Interest income	0.53	4.72	6.05	1.13	0.1	1.23	8.23	9.04	11.6
Pre-tax income	-64.9	-103	-164	-156	-157	11	-16.7	-36.2	88.9
Income tax	0	-0.21	-2.05	5.15	1.39	-172	-30.7	7.04	29.9
Net income	-64.9	-103	-162	-161	-158	183	14.1	-43.2	59
EBITDA	-65.4	-108	-168	-155	-154	12.2	-22.9	-43.9	78.8
EPS, basic	-35.85	-3.49	-2.99	-2.61	-2.30	2.64	0.20	-0.60	0.80
EPS, diluted	-35.85	-3.49	-2.99	-2.61	-2.30	2.60	0.20	-0.60	0.75
Shares, basic (weighted)	1.81	29.5	54	61.8	68.6	69.4	70.1	71.4	74.2
Shares, diluted (weighted)	1.81	29.5	54	61.8	68.6	70.4	71.9	71.4	79

Balance sheet

	FY2018	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Cash and equivalents	45.6	72	46.9	114	122	123	108	184	166
Short-term investments	0	235	186	209	59.7	67.9	98.4	60	248
Receivables					3.99	12.7	21.3	41.7	15.6
Inventory				0	3.68	21.6	31.1	26.4	54.9
Other current assets	1.44	6.45	8.25	9.56	6.59	10.5	17.5	20.1	42.6
Total current assets	47.1	314	242	333	196	243	276	332	527
Property, plant and equipment	0.13	6.36	6.4	4.05	2.83	1.66	0.73	0.66	1.94
Lease right-of-use assets			1.93	6.57	5.55	5.39	11.9	10.4	9.81
Intangible assets				0	19.3	18.3	17.3	16.3	15.3
Other non-current assets				5.59	8.72	5.82	0.83	10.3	11.3
Total assets	47.5	322	255	349	233	460	526	581	764
Accounts payable	1.22	10.9	5.69	0.5	1.87	7.9	8.25	2.04	2.03
Accrued liabilities	6.21	16.4	20.4	29.2	38	30.1	27.7	32.4	42
Deferred revenue							0.31
Total current liabilities	17.4	42.6	27.8	31.8	44.8	47.1	63.7	101	139
Lease liabilities			0.96	4.88	2.67	2.62	10	7.86	6.51
Other non-current liabilities		0.14	0.33	0.81	0.27	1.84	1.86	1.82	18.5
Total liabilities	17.4	42.7	29.1	37.5	47.8	63.5	87.5	142	196
Paid-in capital	1.29	473	581	829	860	888	917	960	1,030
Retained earnings	-91	-194	-356	-517	-675	-492	-478	-521	-462
Other comprehensive income		-0	0.03	-0.03	-0.07	0.04	0.01	-0.16	-0.03
Shareholders' equity	-89.7	279	225	312	185	396	439	438	568
Total equity	-89.7	279	225	312	185	396	439	438	568
Total liabilities and equity	47.5	322	255	349	233	460	526	581	764

Cash flow statement

	FY2018	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Net income	-64.9	-103	-162	-161	-158	183	14.1	-43.2	59
Depreciation and amortization	0.03	0.29	2.07	2.41	2.36	2.4	2.34	1.7	1.55
Stock-based compensation	0.9	5.7	15.1	20.9	25.2	25.1	27.1	30.7	37
Deferred income tax	-0.2	-0.98	-3.16	4.36	0.01	-185	-33.8	8.13	13
Change in receivables					-3.91	-8.68	-8.61	-20.5	26.1
Change in inventory					-3.68	-17.9	-9.52	4.76	-28.5
Change in payables	1.01	8.82	-4.71	-4.97	1.37	6.03	0.35	-6.31	0.14
Cash from operations	-50.2	-81	-158	-137	-126	5.81	13.3	25.7	138
Capital expenditures	-0.07	-5.29	-3.2	-0.28	-0.42	-0.11	-0.13	-0.28	-1.57
Purchases of investments		-402	-489	-430	-157	-136	-205	-202	-387
Cash from investing	-0.07	-239	49.2	-23.4	129	-8.08	-29.6	37.7	-189
Stock issued		0.38	0.59	6.06	5.31	2.61	2.88
Dividends paid	0	0
Cash from financing	39.9	347	84.1	227	5.89	2.52	1.5	12.3	33
Net change in cash	-10.4	26.5	-25	67.1	8.22	0.25	-14.8	75.6	-18
Free cash flow	-50.3	-86.3	-162	-137	-127	5.7	13.2	25.4	136
Income taxes paid	0.29	0.38	1.72	0.48	1.28	10.7	5.61	2	3.01

Key metrics

Worked out from the statements above. Latest values use the trailing twelve months to September 30, 2026; growth uses fiscal years. Valuation uses the share price of $95.02 on November 10, 2026.

Profitability

Metric	Value	How it is calculated
Gross margin	90.2%	Gross profit / revenue.
Operating margin	13.8%	Operating income / revenue.
EBITDA margin	13.9%	EBITDA (operating income + depreciation and amortization) / revenue.
Pre-tax margin	15.5%	Pre-tax income / revenue.
Net margin	11.6%	Net income / revenue.
FCF margin	20.8%	Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin	21.0%	Cash from operations / revenue.
Effective tax rate	25.0%	Income tax / pre-tax income, when pre-tax income is positive.
Return on equity (ROE)	15.4%	Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)	11.1%	Net income / average total assets.
Return on invested capital (ROIC)	15.6%	Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
R&D / revenue	14.4%	Research and development expense / revenue.
SG&A / revenue	26.1%	Selling, general and administrative expense / revenue.
Stock-based pay / revenue	4.8%	Stock-based compensation (from the cash flow statement) / revenue.
Capex / revenue	0.2%	Capital expenditures / revenue.
D&A / revenue	0.1%	Depreciation and amortization / revenue.

Growth

Metric	Value	How it is calculated
Revenue growth, 1y	60.1%	Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y	45.5%	Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Gross profit growth, 1y	65.6%	Gross profit vs the same period a year earlier. Only from a positive base.
Gross profit CAGR, 3y	44.9%	Compound annual growth of gross profit over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Operating income CAGR, 3y	99.2%	Compound annual growth of operating income over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
EBITDA CAGR, 3y	86.3%	Compound annual growth of ebitda over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Net income CAGR, 3y	-31.5%	Compound annual growth of net income over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
EPS CAGR, 3y	-33.9%	Compound annual growth of eps over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Operating cash flow growth, 1y	437.1%	Operating cash flow vs the same period a year earlier. Only from a positive base.
Operating cash flow CAGR, 3y	187.5%	Compound annual growth of operating cash flow over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Free cash flow growth, 1y	436.8%	Free cash flow vs the same period a year earlier. Only from a positive base.
Free cash flow CAGR, 3y	188.1%	Compound annual growth of free cash flow over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value growth, 1y	29.5%	Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y	12.7%	Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y	12.7%	Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y	31.5%	Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y	18.4%	Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y	16.9%	Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y	10.6%	Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y	3.9%	Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y	5.0%	Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.

Balance sheet health

Metric	Value	How it is calculated
Current ratio	3.91x	Current assets / current liabilities.
Quick ratio	3.12x	(Cash + short-term investments + receivables) / current liabilities.
Cash ratio	2.96x	(Cash + short-term investments) / current liabilities.
Liabilities / assets	27.8%	Total liabilities / total assets.
Working capital	$558.2M	Current assets - current liabilities.
Goodwill and intangibles / assets	1.5%	(Goodwill + intangible assets) / total assets.
Tangible book value	$695.7M	Shareholders' equity - goodwill - intangible assets.

Efficiency

Metric	Value	How it is calculated
Asset turnover	0.96x	Revenue / average total assets.
Fixed asset turnover	384x	Revenue / average property, plant and equipment.
Inventory turnover	0.86x	Cost of revenue / average inventory.
Days inventory	424 days	365 x average inventory / cost of revenue.
Receivables turnover	30.7x	Revenue / average receivables.
Days sales outstanding	12 days	365 x average receivables / revenue.
Days payables	16 days	365 x average accounts payable / cost of revenue.
Cash conversion cycle	419 days	Days inventory + days sales outstanding - days payables.
FCF conversion	180.0%	Free cash flow / net income, when net income is positive.
Capex / operating cash flow	0.8%	Capital expenditures / cash from operations, when that is positive.

Per share

Metric	Value	How it is calculated
EPS, diluted	$1.29	Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share	$11.14	Revenue / diluted weighted shares.
FCF per share	$2.32	Free cash flow / diluted weighted shares.
Operating cash flow per share	$2.34	Cash from operations / diluted weighted shares.
Book value per share	$8.36	Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Tangible book per share	$8.19	Tangible book value / shares outstanding.
Cash per share	$6.70	(Cash + short-term investments) / shares outstanding.

Valuation

Metric	Value	How it is calculated
Market cap	$7.41B	Share price x shares outstanding.
Enterprise value	$6.85B	Market cap + total debt - cash - short-term investments.
P/E	67.7x	Market cap / net income. Only when net income is positive.
P/S	7.84x	Market cap / revenue.
P/B	10.4x	Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book	10.7x	Market cap / tangible book value, when positive.
P/FCF	37.6x	Market cap / free cash flow. Only when free cash flow is positive.
P/OCF	37.3x	Market cap / cash from operations, when positive.
EV/Sales	7.24x	Enterprise value / revenue.
EV/EBIT	52.5x	Enterprise value / operating income, when both are positive.
EV/EBITDA	52.0x	Enterprise value / EBITDA, when both are positive.
EV/FCF	34.7x	Enterprise value / free cash flow, when both are positive.
FCF yield	2.7%	Free cash flow / market cap.
Earnings yield	1.5%	Net income / market cap (the inverse of P/E).

What was Kiniksa Pharmaceuticals International, plc's revenue in fiscal 2025?

Kiniksa Pharmaceuticals International, plc reported revenue of $677.6M for fiscal 2025, 60.1% higher than the year before.

Was Kiniksa Pharmaceuticals International, plc profitable in fiscal 2025?

Yes. Net income was $59.0M, a net margin of 8.7%.

How much free cash flow did Kiniksa Pharmaceuticals International, plc generate in fiscal 2025?

Cash from operations of $138.0M minus capital expenditures of $1.6M left free cash flow of $136.4M.

Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.

Open interactive statements, quarterly figures and charts

Back to Kiniksa Pharmaceuticals International, plc